Method using crystal structure of estrogen receptor-β complex
View Patent ↗This invention is directed to the crystal structure of Estrogen Receptor-β (ER-β) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-β, which may be useful as novel chemotherapeutic agents.
1. A method for identifying an agent that interacts with ER-β, the method comprising:
(a) providing a crystal structure of ER-β, having a resolution of 1.83 Å or less;
(b) generating a three dimensional model of ER-β using the relative structural coordinates according to FIGS. 2 A- 2 XX, ±a root mean square deviation from the backbone atoms of the amino acids of not more than 1.5 Å, the relative structural coordinates being based on the crystal structure of ER-β; and
(c) employing the three-dimensional model to design or select an agent that interacts with ER-β.
2. The method of claim 1 , further comprising:
(d) obtaining the agent; and
(e) contacting the agent with ER-β in order to determine the effect the agent has on ER-β activity.
3. A method for identifying an activator or inhibitor of ER-β, the method comprising:
(a) providing a crystal structure of ER-β having a resolution of 1.83 Å or less;
(b) generating a three dimensional model of ER-β using (i) the relative structural coordinates of amino acid residues MET343, LEU346, LEU349, GLU353, MET384, LEU387, MET388, ARG394, PHE404, ILE421, ILE424, GLY520, HIS523 and LEU524 according to FIGS. 2 A- 2 XX for monomer A of ER-β, ± a root mean square deviation from the backbone atoms of the amino acids of not more than 1.5 ÅA, the relative structural coordinates of the amino acid residues for monomer A of ER-β being based on the crystal structure of ER-β or (ii) the relative structural coordinates of amino acid residues MET343, LEU346, LEU349, GLU353, MET384, LEU387, MET388, LEU391, ARG394, PHE404, ILE421, ILE424, GLY520, HIS523 and LEU524 according to FIG. 2 for monomer B of ER-β±, a root mean square deviation from the backbone atoms of the amino acids of not more than 1.5 Å, the relative structural coordinates of the amino acid residues for monomer B of ER-β being based on the crystal structure of ER-β; and
(c) selecting or designing a candidate activator or inhibitor by performing computer fitting analysis of the candidate activator or inhibitor with the three dimensional model generated in step (b).
4. The method of claim 3 , wherein the structural coordinates according to (i) further comprise the relative structural coordinates of amino acid residues VAL328, MET342, SER345, THR347, LYS348, LEU349, ALA350, ASP351, LEU354, MET357, TRP383, GLU385, VAL386, MET389, GLY390, LEU391, MET392, LEU402, ILE403, ALA405, LEU408, VAL418, GLU419, GLY420, LEU422, GLU423, PHE425, LEU428, ALA516, SER517, LYS519, MET521, GLU522, LEU525, ASN526, MET527, LYS528, VAL533, VAL535, TYR536 and LEU538 according to FIGS. 2 A- 2 XX for monomer A of ER-β, ± a root mean square deviation from the backbone atoms of the amino acids of not more than 1.5 Å, the relative structural coordinates of the amino acid residues for monomer A of ER-β being based on the crystal structure of ER-β.
5. The method of claim 3 , wherein the relative structural coordinates according to (ii) further comprise the relative structural coordinates of amino acid residues MET342, SER345, THR347, LYS348, ALA350, ASP351, MET357, TRP383, GLU385, VAL386, LEU387, MET389, GLY390, MET392, LEU402, ILE403, ALA405, LEU408, VAL418, GLU419, GLY420, LEU422, GLU423, PHE425, LEU428, ALA516, SER517, LYS519, MET521, GLU522, LEU525, ASN526, MET527, LYS528, VAL533, TYR536 and LEU538 according to FIGS. 2 A- 2 XX for monomer B of ER-β, ± a root mean square deviation from the backbone atoms of the amino acids of not more than 1.5 Å, the relative structural coordinates of the amino acid residues for monomer B of ER-β being based on the crystal structure of ER-β.
6. The method of claim 3 , further comprising the steps of:
(d) obtaining the candidate activator or inhibitor; and
(e) contacting the candidate activator or inhibitor with the molecule or molecular complex and determining the effect the candidate activator or inhibitor has on the molecule or molecular complex.
7. The method of claim 6 , wherein the candidate activator or inhibitor is contacted with the molecule or molecular complex in the presence of genistein to determine the effect the candidate activator or inhibitor has on binding of the molecule or molecular complex to genistein.
8. The method of claim 1 , wherein the crystal structure of ER- 62 has a resolution of 1.8 Å.
9. The method of claim 3 , wherein the crystal structure of ER-β has a resolution of 1.8 Å.